GlobeNewswire Inc | Feb 18, 2021 08:00AM EST

February 18, 2021

~ Strong 4Q sequential sales and profit increase ~~W0:~ 4Q sales at the high end of guidance, profit above guidance ~ ~ Strong cash management reduced net total debt by $123 million in 2020 ~

PLANO, Texas, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three and twelve months ended December 31, 2020. Unless otherwise stated, all results and comparisons are from continuing operations.

Executing strategy through the COVID-19 pandemic

-- Throughout the pandemic, Integer associates continue to deliver critical products that customers and patients rely on every day. -- Integers Manufacturing Excellence strategic imperative delivered strong operational results in 2020, delivering productivity and continued improvements in safety, quality and on-time delivery. -- Integer continues to invest in its product line and operational strategy to create long-term value, including manufacturing capabilities, R&D resources and talent additions to execute the strategic imperatives.

Fourth Quarter 2020 Financial Results (compared to fourth quarter 2019, except as noted)

-- Integer delivered fourth quarter sales at the high end of guidance and profit above guidance. -- Strong sequential improvement versus the third quarter including margin expansion on sales recovery and continued operating efficiencies. -- Sales declined 17% to $269 million. -- GAAP net income grew $4 million to $15 million, an increase of 40%. Adjusted net income declined $18 million to $23 million, a decrease of 43%. -- Adjusted EBITDA declined $24 million to $49 million, a decrease of 33%. -- GAAP diluted EPS grew $0.14 per share to $0.47 per share, an increase of 42%. Adjusted EPS declined $0.54 per share to $0.71 per share, a decrease of 43%. -- Net total debt decreased $59 million from the end of the third quarter 2020 to $689 million.

Full Year 2020 Financial Results (compared to full year 2019)

-- Sales declined 15% to $1.073 billion. -- GAAP net income declined $14 million to $77 million, a decrease of 15%. Adjusted net income declined $63 million to $92 million, a decrease of 41%. -- GAAP diluted EPS declined $0.43 per share to $2.33 per share, a decrease of 16%. Adjusted EPS declined $1.91 per share to $2.77 per share, a decrease of 41%. -- Adjusted EBITDA declined $94 million to $190 million, a decrease of 33%. -- Generated $181 million of cash flow from operating activities. -- Reduced net total debt by $123 million.

Our fourth quarter results reflect the beginning of the recovery from the pandemic as both sales and profit improved significantly from the third quarter, said Joseph Dziedzic, Integers president and CEO. Integers dedicated associates continued to deliver for our customers and their patients while executing our strategy to achieve excellence in everything we do. Our strong operational performance and continued strong cash generation last year enabled Integer to increase investments in our strategy versus 2019. During 2020, Integer improved our manufacturing processes, enhanced our customer relationships, built and added leadership capability and strengthened our culture, positioning 2021 to be a return to profitable growth on our Journey to Excellence.

Discussion of Product Line Fourth Quarter and Full Year Sales

-- Cardio & Vascular sales declined 14% in the fourth quarter and full year sales declined 7%. Sales were negatively impacted by the COVID-19 pandemic and a blend of our customers responses across nearly all C&V markets. -- Cardiac & Neuromodulation sales declined 21% in the fourth quarter and full year sales declined 24%. CRM and Neuromodulation declined due to the COVID-19 pandemic impact and a blend of our customers responses. Additionally, the fourth quarter 2019 Nuvectra bankruptcy created a $17 million headwind for the full year. -- Advanced Surgical, Orthopedics & Portable Medical includes sales to the acquirer of our AS&O product line, Viant, under supply agreements associated with the divestiture. Fourth quarter sales declined 12% and full year sales decreased 8%, driven by the COVID-19 pandemic impact and a blend of our customers responses. -- Electrochem sales declined 41% in the fourth quarter and full year sales declined 39% driven by a severe decline in the energy market and demand fall-out from the COVID-19 pandemic.

2021 Outlook

Our full year 2021 financial outlook reflects an expected recovery of the industry with year-over-year sales growth projected to be 8% to 12%. Integers first quarter sales are projected to be sequentially better than the fourth quarter of 2020and we believe the second quarter should be similar or slightly better than the first quarter. We expect the improvement in the second half of 2021 to be determined by the pace of COVID-19 recovery.

We expect our operating income to reflect the increase in sales and the continued execution of our manufacturing excellence strategic imperative. We project to generate $90 to $110 of free cash flow, with an equivalent amount of net total debt reduction.

2021 Outlook(a)(dollars in millions, except per share amounts)

First Quarter 2021

GAAP Non-GAAP^(b) As Reported Change Adjusted ChangeSales $280 to (15)% to (12) $280 to (15)% to (12) $290 % $290 %Operating $29 to $34 (34)% to (23) $42 to $47 (29)% to (20)income % %

Full Year 2021

GAAP Non-GAAP^(b) As Reported Change Adjusted ChangeSales $1,160 to 8% to $1,160 to 8% to $1,200 12% $1,200 12%Operating income $116 to $136 (4)% to $170 to $190 18% to 13% 32%EBITDA N/A N/A $230 to $250 21% to 32%Net income $74 to $91 (4)% to $113 to $130 23% to 18% 41%Earnings per Diluted $2.24 to (4)% to $3.40 to 23% toShare $2.74 17% $3.90 41%

Except as described below, further reconciliations by line item to the closest corresponding GAAP financial measure for Adjusted operating income,^ Adjusted EBITDA, Adjusted net income, and Adjusted Earnings per Share(a) (?EPS?), all from continuing operations, included in our ?2021 Outlook? above, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from these non-GAAP financial measures. Adjusted operating income for 2021 is expected to consist of GAAP operating income, excluding items such as intangible amortization, certain legal expenses, reorganization and realignment costs, asset dispositions and severance, totaling approximately $54 million ($13 million for first quarter), pre-tax. Adjusted net income and Adjusted EPS for 2021 are^ expected to consist of GAAP net income and diluted EPS, excluding items(b) such as intangible amortization, certain legal expenses, reorganization and realignment costs, asset dispositions, severance, gains and losses on equity investments and loss on extinguishment of debt totaling approximately $49 million, pre-tax. The after-tax impact of these items is estimated to be approximately $39 million, or approximately $1.16 per diluted share.

Adjusted EBITDA is expected to consist of Adjusted net income, excluding items such as depreciation, interest, stock-based compensation and taxes totaling approximately $116 million to $120 million.

Supplemental Financial Information

2021 2020 Outlook ActualCapital Expenditures, Net $50 - $60 $47 Depreciation and Amortization $80 - $90 $79 Stock-Based Compensation $17 - $19 $9 Other Operating Expense $8 - $12 $8 Adjusted Effective Tax Rate 15.5% - 17.5% 12.2% Cash Tax Payments $20 - $27 $18

Summary of Financial and Product Line Results from Continuing Operations

(dollars in thousands, except per share data)

Three Months Ended December 31, December 31, OrganicGAAP 2020 2019 Change Change^ (a)Medical Sales Cardio & Vascular $ 137,063 $ 158,504 (13.5 ) % (14.3 ) %Cardiac & 93,838 119,262 (21.3 ) % (21.3 ) %NeuromodulationAdvanced Surgical,Orthopedics & 29,747 33,885 (12.2 ) % (12.2 ) %Portable MedicalTotal Medical Sales 260,648 311,651 (16.4 ) % (16.7 ) %Non-Medical Sales 8,311 13,986 (40.6 ) % (40.6 ) %Total Sales $ 268,959 $ 325,637 (17.4 ) % (17.8 ) % Income fromcontinuing $ 15,427 $ 11,044 39.7 % operationsDiluted EPS fromcontinuing $ 0.47 $ 0.33 42.4 % operations Year Ended December 31, December 31, OrganicGAAP 2020 2019 Change Change^ (a)Medical Sales Cardio & Vascular $ 569,948 $ 610,056 (6.6 ) % (7.7 ) %Cardiac & 346,242 457,194 (24.3 ) % (24.3 ) %NeuromodulationAdvanced Surgical,Orthopedics & 121,788 132,429 (8.0 ) % (8.0 ) %Portable MedicalTotal Medical Sales 1,037,978 1,199,679 (13.5 ) % (14.0 ) %Non-Medical Sales 35,464 58,415 (39.3 ) % (39.3 ) %Total Sales $ 1,073,442 $ 1,258,094 (14.7 ) % (15.2 ) % Income fromcontinuing $ 77,258 $ 91,218 (15.3 ) % operationsDiluted EPS fromcontinuing $ 2.33 $ 2.76 (15.6 ) % operations

Organic sales change is a Non-GAAP measure. Please see ?Notes Regarding^ Non-GAAP Financial Information? for additional information regarding our(a) use of non-GAAP financial measures and refer to Table C at the end of this release for a reconciliation of these amounts.

Three Months EndedNon-GAAP^(a) December 31, December 31, Change Organic Change^ 2020 2019 (b)Adjusted EBITDA $ 49,236 $ 73,273 (32.8 ) % (30.6 ) %Adjusted net $ 23,424 $ 41,421 (43.4 ) % (40.4 ) %incomeAdjusted EPS $ 0.71 $ 1.25 (43.2 ) % (40.5 ) % Year EndedNon-GAAP^(a) December 31, December 31, Change Organic Change^ 2020 2019 (b)Adjusted EBITDA $ 189,616 $ 283,770 (33.2 ) % (32.9 ) %Adjusted net $ 91,849 $ 154,468 (40.5 ) % (39.8 ) %incomeAdjusted EPS $ 2.77 $ 4.68 (40.8 ) % (40.0 ) %

^ Refer to Tables A and B at the end of this release for reconciliations of(a) adjusted amounts to the closest corresponding GAAP financial measures. Organic change rates for Adjusted EBITDA from continuing operations,^ Adjusted net income, and Adjusted EPS are Non-GAAP measures. Please see(b) ?Notes Regarding Non-GAAP Financial Information? for additional information regarding our use of non-GAAP financial measures and refer to Table D at the end of this release for a reconciliation of these amounts.

Conference Call InformationThe Company will host a conference call on Thursday, February 18, 2021, at 9:00 a.m. EDT / 8:00 a.m. CDT to discuss these results. The scheduled conference call will be webcast live and is accessible through our website at investor.integer.net or by dialing (833) 714-0898 (U.S.) or (778) 560-2691 (outside U.S.) and the conference ID is 1898248. The call will be archived on the Companys website. An earnings call slide presentation containing supplemental information about the Companys results will be posted to our website at investor.integer.net prior to the conference call and will be referenced during the conference call.

From time to time, the Company posts information that may be of interest to investors on its website at investor.integer.net. To automatically receive Integer financial news by email, please visit investor.integer.net and subscribe to email alerts.

About IntegerInteger Holdings Corporation(NYSE: ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical, Lake Region Medical and Electrochem. Additional information is available atwww.integer.net.

Contact InformationTony BorowiczSVP, Strategy, Business Development & Investor Relations716.759.5809tony.borowicz@integer.net

Notes Regarding Non-GAAP Financial Information

In addition to our results reported in accordance with generally accepted accounting principles in the United States of America (GAAP), we provide adjusted net income, adjusted EPS, earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted EBITDA, adjusted EBITDA margin, adjusted operating income, adjusted operating income margin, and organic change rates, all from continuing operations. Adjusted net income and adjusted EPS consist of GAAP amounts from continuing operations adjusted for the following to the extent occurring during the period: (i) acquisition and integration related expenses, including fair value adjustments to contingent consideration resulting from acquisitions, (ii) amortization of intangible assets, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain legal expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) (gain) loss on equity investments, (ix) extinguishment of debt charges, (x) the income tax provision (benefit) related to these adjustments and (xi) certain tax items that are outside the normal tax provision for the period. Adjusted EPS is calculated by dividing adjusted income from continuing operations by diluted weighted average shares outstanding. EBITDA is calculated by adding back interest expense, GAAP provision (benefit) for income taxes, depreciation and amortization expense, to income from continuing operations, which is the most directly comparable GAAP measure. Adjusted EBITDA consists of EBITDA plus GAAP stock-based compensation and the same adjustments as listed above except for items (ii), (ix), (x) and (xi).

Adjusted operating income consists of operating income from continuing operations adjusted for the same items listed above except for items (viii), (ix), (x) and (xi). Adjusted operating income margin is adjusted operating income as a percentage of sales.

Adjusted EBITDA margin is adjusted EBITDA as a percentage of sales. Organic sales change is reported sales growth adjusted for the impact of foreign currency and the contribution of acquisitions. To calculate the impact of foreign currency on sales growth rates, we convert any sale made in a foreign currency by converting current period sales into prior period sales using the exchange rate in effect at that time and then compare the two, negating any effect foreign currency had on our transactional revenue, and exclude the amount of sales acquired or divested during the period from the current/previous period amounts, respectively.

Organic change rates for adjusted EBITDA, adjusted net income and adjusted EPS exclude the impact of foreign currency exchange gains and losses included in other (income) loss, net, and the contribution of acquisitions. Contribution of acquisitions represents results, based on the growth rate being presented, attributable to acquired entities for the first four full quarters plus any partial period since the entities' acquisition date. After the completion of four full fiscal quarters, results of the acquired entity are treated as organic for current and comparable historical periods.

We believe that the presentation of adjusted net income, adjusted EPS, EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted operating income, adjusted operating income margin, and organic change rates, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations. In addition to the performance measures identified above, we believe that net total debt and leverage ratio provide meaningful measures of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of acquisitions and debt repayments. Net total debt is calculated as total principal amount of debt outstanding less cash and cash equivalents. We calculate leverage ratio as net total debt divided by adjusted EBITDA for the trailing 4 quarters.

Forward-Looking Statements

Some of the statements contained in this press release are forward-looking statements within the meaning of Section27A of the Securities Act of 1933, as amended, and Section21E of the Securities Exchange Act of 1934, as amended, including statements relating to the impact of the COVID-19 global pandemic; future sales, expenses, and profitability; future development and expected growth of our business and industry; our ability to execute our business model and our business strategy; having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and projected capital spending. You can identify forward-looking statements by terminology such as may, will, should, could, expects, intends, plans, anticipates, believes, estimates, predicts, potential or continue or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: the duration, scope and impact of the COVID-19 pandemic, including government, social, business and other actions taken in response to the pandemic and the effect of the pandemic on our associates, suppliers and customers as well as the global economy; our dependence upon a limited number of customers; pricing pressures that we face from customers; our ability to respond to changes in technology; the intense competition we face and our ability to successfully market our products; our ability to develop new products and expand into new geographic and product markets; our reliance on third party suppliers for raw materials, key products and subcomponents; the potential for harm to our reputation caused by quality problems related to our products; regulatory issues resulting from product complaints, recalls or regulatory audits; the potential of becoming subject to product liability claims; our ability to protect our intellectual property and proprietary rights; our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under our senior secured credit facilities; our ability to integrate acquisitions and operate acquired businesses in accordance with expectations; our dependence upon our senior management team and technical personnel; our ability to realize the benefits from cost savings and consolidation initiatives; interruptions in our manufacturing operations; our ability to comply with environmental regulations; our complex international tax profile; our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures; market, financial and other risks related to our international operations and sales; global economic factors, including currency exchange rates and interest rates; the fact that the healthcare industry is highly regulated and subject to various regulatory changes; the dependence of our energy market-related revenues on the conditions in the oil and natural gas industry; and other risks and uncertainties that arise from time to time and are described in Item1A Risk Factors of our Annual Report on Form 10-K and in our other periodic filings with the SEC. Except as may be required by law, we assume no obligation to update forward-looking statements in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

Condensed Consolidated Statements of Operations - Unaudited(in thousandsexcept per share data) Three Months Ended Year Ended December 31, December 31, December 31, December 31, 2020 2019 2020 2019Sales $ 268,959 $ 325,637 $ 1,073,442 $ 1,258,094 Cost of sales 195,750 249,607 787,735 903,084 Gross profit 73,209 76,030 285,707 355,010 Operating expenses:Selling,general and 35,037 37,661 109,006 138,695 administrative(SG&A)Research,development 10,589 11,809 48,468 46,529 andengineeringOtheroperating (10 ) 3,912 7,621 12,151 expenses (OOE)Totaloperating 45,616 53,382 165,095 197,375 expensesOperating 27,593 22,648 120,612 157,635 incomeInterest 9,218 12,766 38,220 52,545 expense(Gain) loss onequity (1,383 ) (191 ) (5,337 ) 475 investments,netOther (income) 1,755 343 1,522 (578 ) loss, netIncome fromcontinuingoperations 18,003 9,730 86,207 105,193 before incometaxesProvision(benefit) for 2,576 (1,314 ) 8,949 13,975 income taxesIncome fromcontinuing $ 15,427 $ 11,044 $ 77,258 $ 91,218 operations Discontinued operations:Income (loss)fromdiscontinued ? (20 ) ? 5,296 operationsbefore taxesProvision for ? ? ? 178 income taxesIncome (loss)from $ ? $ (20 ) $ ? $ 5,118 discontinuedoperations Net income $ 15,427 $ 11,024 $ 77,258 $ 96,336 Basic earnings per share:Income fromcontinuing $ 0.47 $ 0.34 $ 2.35 $ 2.80 operationsIncome fromdiscontinued $ ? $ ? $ ? $ 0.16 operationsBasic earnings $ 0.47 $ 0.34 $ 2.35 $ 2.95 per share Dilutedearnings per share:Income fromcontinuing $ 0.47 $ 0.33 $ 2.33 $ 2.76 operationsIncome fromdiscontinued $ ? $ ? $ ? $ 0.15 operationsDilutedearnings per $ 0.47 $ 0.33 $ 2.33 $ 2.92 share Weightedaverage shares outstanding:Basic 32,880 32,688 32,845 32,627 Diluted 33,129 33,089 33,113 33,037

Condensed Consolidated Balance Sheets - Unaudited(in thousands) December 31, December 31, 2020 2019ASSETS Current assets: Cash and cash equivalents $ 49,206 $ 13,535 Accounts receivable, net 156,207 191,985 Inventories 149,323 167,256 Refundable income taxes 2,087 ? Contract assets 40,218 24,767 Prepaid expenses and other current assets 15,896 17,852 Total current assets 412,937 415,395 Property, plant and equipment, net 253,964 246,185 Goodwill 859,442 839,617 Other intangible assets, net 757,224 775,784 Deferred income taxes 4,398 4,438 Operating lease assets 45,153 42,379 Other long-term assets 38,739 29,295 Total assets $ 2,371,857 $ 2,353,093 LIABILITIES AND STOCKHOLDERS? EQUITY Current liabilities: Current portion of long-term debt $ 37,500 $ 37,500 Accounts payable 51,570 64,975 Income taxes payable 1,847 3,023 Current portion of lease liabilities 8,431 7,507 Accrued expenses and other current liabilities 56,843 66,073 Total current liabilities 156,191 179,078 Long-term debt 693,758 777,272 Deferred income taxes 182,304 187,978 Operating lease liabilities 37,861 37,114 Other long-term liabilities 30,688 19,163 Total liabilities 1,100,802 1,200,605 Stockholders? equity: Common stock 33 33 Additional paid-in capital 700,814 701,018 Treasury stock ? (8,809 ) Retained earnings 517,516 440,258 Accumulated other comprehensive income 52,692 19,988 Total stockholders? equity 1,271,055 1,152,488 Total liabilities and stockholders? equity $ 2,371,857 $ 2,353,093

Condensed Consolidated Statements of Cash Flows^(a) - Unaudited(in thousands) Year Ended December 31, December 31, 2020 2019Cash flows from operating activities: Net income $ 77,258 $ 96,336 Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization 79,324 77,895 Debt related charges included in interest expense 4,774 7,772 Stock-based compensation 9,163 9,294 Non-cash charges related to customer bankruptcy 554 21,695 Non-cash lease expense 7,810 7,443 Non-cash (gain) loss on equity investments (5,337 ) 475 Contingent consideration fair value adjustment (2,000 ) ? Other non-cash (gains) losses 600 (162 ) Deferred income taxes (6,966 ) (10,285 ) Gain on sale of discontinued operations ? (4,974 ) Changes in operating assets and liabilities, net of acquisitions:Accounts receivable 38,153 (6,976 ) Inventories 18,441 3,724 Prepaid expenses and other assets (864 ) (6,293 ) Contract assets (15,451 ) (24,767 ) Accounts payable (9,055 ) 1,887 Accrued expenses and other liabilities (10,721 ) (2,744 ) Income taxes (4,342 ) (4,962 ) Net cash provided by operating activities 181,341 165,358 Cash flows from investing activities: Acquisition of property, plant and equipment (46,832 ) (48,198 ) Purchase of intangible asset (4,607 ) ? Proceeds from sale of property, plant and equipment 82 28 Purchase of equity investments ? (417 ) Proceeds from sale of discontinued operations ? 4,734 Acquisitions, net (5,219 ) (15,009 ) Net cash used in investing activities (56,576 ) (58,862 ) Cash flows from financing activities: Principal payments of long-term debt (87,500 ) (111,500 ) Proceeds from senior secured revolving line of 185,000 34,000 creditPayments of senior secured revolving line of credit (185,000 ) (39,000 ) Proceeds from the exercise of stock options 3,263 3,242 Payment of debt issuance costs (515 ) (1,385 ) Tax withholdings related to net share settlements (3,820 ) (3,283 ) of restricted stock unit awardsPrincipal payments on finance leases (6 ) ? Net cash used in financing activities (88,578 ) (117,926 ) Effect of foreign currency exchange rates on cash (516 ) (604 ) and cash equivalentsNet increase (decrease) in cash and cash 35,671 (12,034 ) equivalentsCash and cash equivalents, beginning of year 13,535 25,569 Cash and cash equivalents, end of year $ 49,206 $ 13,535

^ The Condensed Consolidated Statements of Cash Flows - Unaudited includes(a) cash flows related to discontinued operations.

Reconciliations of Non-GAAP Measures from Continuing OperationsTable A: Income from Continuing Operations and Diluted EPS Reconciliations(dollars in thousands, except per share data)

Three Months Ended December 31, 2020 December 31, 2019 Net of Per Net of Per Pre-Tax Tax Diluted Pre-Tax Tax Diluted Share ShareIncome fromcontinuing $ 18,003 $ 15,427 $ 0.47 $ 9,730 $ 11,044 $ 0.33 operations (GAAP)Adjustments^(a): Amortization of 10,237 8,095 0.24 10,609 8,310 0.25 intangiblesCertain legalexpenses (SG&A)^ 139 111 ? 402 318 0.01 (b)Other operating (10 ) 235 0.01 3,912 3,020 0.09 expenses (OOE)^(c)Gain on equity (1,383 ) (1,093 ) (0.03 ) (191 ) (150 ) ? investments, netLoss onextinguishment of 550 435 0.01 1,280 1,012 0.03 debtCustomerbankruptcy 16 13 ? 23,827 18,823 0.57 (excluding OOE)^(d)Tax adjustments ? 201 0.01 ? (956 ) (0.03 ) Adjusted net $ 27,552 $ 23,424 $ 0.71 $ 49,569 $ 41,421 $ 1.25 income (Non-GAAP) Diluted weightedaverage shares for 33,129 33,089 adjusted EPS Year Ended December 31, 2020 December 31, 2019 Net of Per Net of Per Pre-Tax Tax Diluted Pre-Tax Tax Diluted Share ShareIncome fromcontinuing $ 86,207 $ 77,258 $ 2.33 $ 105,193 $ 91,218 $ 2.76 operations (GAAP)Adjustments^(a): Amortization of 41,131 32,520 0.98 40,076 31,634 0.96 intangiblesCertain legalexpenses (gains) (26,811 ) (21,180 ) (0.64 ) 2,577 2,036 0.06 (SG&A)^(b)Other operating 7,621 6,177 0.19 12,151 9,326 0.28 expenses (OOE)^(c)(Gain) loss onequity (5,337 ) (4,216 ) (0.13 ) 475 376 0.01 investments, netLoss onextinguishment of 550 435 0.01 2,545 2,011 0.06 debtCustomerbankruptcy 1,229 971 0.03 23,827 18,823 0.57 (excluding OOE)^(d)Tax adjustments ? (116 ) ? ? (956 ) (0.03 ) Adjusted net $ 104,590 $ 91,849 $ 2.77 $ 186,844 $ 154,468 $ 4.68 income (Non-GAAP) Diluted weightedaverage shares for 33,113 33,037 adjusted EPS^(l)

The difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment. Net of tax amounts are^ computed using a 21% U.S. tax rate, and the statutory tax rates applicable(a) in foreign tax jurisdictions, as adjusted for the existence of net operating losses (?NOLs?). Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%. Represents the net gain of $28.2 million, recorded during the third quarter^ of 2020 and received in the fourth quarter of 2020, in connection with the(b) resolution of the AVX Corporation patent litigation matter, as well as expenses associated with non-ordinary course legal matters. Other operating expenses includes acquisition and integration related expenses, facility consolidation, optimization, manufacturing transfer and^ system integration charges, asset write-down and disposition charges,(c) charges in connection with corporate realignments or a reduction in force, unusual or infrequently occurring items. Other operating expenses for the fourth quarter of 2020 includes a $1.5 million adjustment to reduce the the fair value of acquisition-related contingent consideration liabilities. In November 2019, one of our customers, Nuvectra Corporation, filed a voluntary Chapter 11 bankruptcy petition (the ?Customer Bankruptcy?). During the fourth quarter of 2019, we recorded pre-tax charges totaling $24.2 million in connection with the Customer Bankruptcy. These expenses were primarily non-cash and included charges associated with certain^ Nuvectra-related assets, primarily consisting of inventory, accounts(d) receivable, as well as certain non-cancelable inventory commitments. These charges were included in cost of sales ($21.4 million), SG&A expenses ($2.4 million) and Other Operating Expenses ($0.4 million) in our consolidated statement of operations. During 2020, we incurred costs and recorded charges associated with the Customer Bankruptcy, primarily consisting of charges related to inventory recorded in cost of sales in our consolidated statement of operations.

Please see Notes Regarding Non-GAAP Financial Information for additional information regarding our use of non-GAAP financial measures.

Table B: EBITDA and Sales Reconciliations(in thousands)

Three Months Ended Year Ended December 31, December 31, December 31, December 31, 2020 2019 2020 2019Income fromcontinuing $ 15,427 $ 11,044 $ 77,258 $ 91,218 operations(GAAP) Interest 9,218 12,766 38,220 52,545 expenseProvision(benefit) 2,576 (1,314 ) 8,949 13,975 for incometaxesDepreciation 10,082 9,889 38,193 37,819 Amortizationof 10,237 10,609 41,131 40,076 intangiblesEBITDA fromcontinuing 47,540 42,994 203,751 235,633 operations(Non-GAAP)Certainlegal 139 402 (26,811 ) 2,577 expenses(gains)Stock-basedcompensation 2,934 2,329 9,163 9,107 (excludingOOE)Otheroperating (10 ) 3,912 7,621 12,151 expenses(OOE)(Gain) losson equity (1,383 ) (191 ) (5,337 ) 475 investments,netCustomerbankruptcy(excluding 16 23,827 1,229 23,827 amounts inOOE)AdjustedEBITDA $ 49,236 $ 73,273 $ 189,616 $ 283,770 (Non-GAAP) Total sales $ 268,959 $ 325,637 $ 1,073,442 $ 1,258,094 (GAAP) AdjustedEBITDA 18.3 % 22.5 % 17.7 % 22.6 %margin

Table C: Organic Sales from Continuing Operations Change Reconciliation (% Change)

GAAP Impact of Non-GAAP Reported Acquisitions Organic Growth and Foreign Change Currency^(a)Quarter over Quarter Change (4Q 2020 vs. 4Q 2019)Medical Sales Cardio & Vascular (13.5)% (0.8)% (14.3)%Cardiac & Neuromodulation (21.3)% ? (21.3)%Advanced Surgical, Orthopedics & Portable (12.2)% ? (12.2)%MedicalTotal Medical Sales (16.4)% (0.3)% (16.7)%Non-Medical Sales (40.6)% ? (40.6)%Total Sales (17.4)% (0.4)% (17.8)% Year over Year Change (2020 vs. 2019) Medical Sales Cardio & Vascular (6.6)% (1.1)% (7.7)%Cardiac & Neuromodulation (24.3)% ? (24.3)%Advanced Surgical, Orthopedics & Portable (8.0)% ? (8.0)%MedicalTotal Medical Sales (13.5)% (0.5)% (14.0)%Non-Medical Sales (39.3)% ? (39.3)%Total Sales (14.7)% (0.5)% (15.2)%

^ Fourth quarter and full year 2020 and 2019 sales have been adjusted to(a) exclude the contribution of business acquisitions and foreign currency exchange rate fluctuations.

Table D: Non-GAAP Organic Change Reconciliation (% Change)

GAAP Impact of Impact of Non-GAAP Reported Non-GAAP Acquisitions Organic Growth^ Adjustments and Foreign Change (a) ^(b) Currency^(c)Quarter over Quarter Change (4Q 2020 vs. 4Q 2019)EBITDA from continuing 10.6% (43.4)% 2.2% (30.6)%operationsIncome from continuing 39.7% (83.1)% 3.0% (40.4)%operationsDiluted EPS from continuing 42.4% (85.6)% 2.7% (40.5)%operations Year over Year Change (2020 vs. 2019)EBITDA from continuing (13.5)% (19.7)% 0.3% (32.9)%operationsIncome from continuing (15.3)% (25.2)% 0.7% (39.8)%operationsDiluted EPS from continuing (15.6)% (25.2)% 0.8% (40.0)%operations

^ EBITDA is a non-GAAP financial measure. See Table B for a reconciliation to(a) the most comparable GAAP measure.^ Represents the impact to our growth rate from our Non-GAAP adjustments. See(b) Tables A and B for further detail on these items. Represents the impact to our growth rate due to changes in foreign currency^ exchange rates realized in income and reported in other (income) loss, net(c) in the consolidated statements of operations, and the adjustment to exclude the contribution of acquisitions when applicable.

Table E: Net Total Debt Reconciliation(in thousands)

December 31, December 31, 2020 2019Current portion of long-term debt $ 37,500 $ 37,500 Long-term debt 693,758 777,272 Total debt 731,258 814,772 Add: Unamortized discount and debt issuance costs 6,715 10,702 Total principal amount of debt outstanding 737,973 825,474 LESS: Cash and cash equivalents 49,206 13,535 Net Total Debt (Non-GAAP) $ 688,767 $ 811,939